326 related articles for article (PubMed ID: 16886645)
1. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
3. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
5. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
6. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
7. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
8. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
[TBL] [Abstract][Full Text] [Related]
9. New and traditional serum markers of bone metabolism in the detection of skeletal metastases.
Plebani M; Bernardi D; Zaninotto M; De Paoli M; Secchiero S; Sciacovelli L
Clin Biochem; 1996 Feb; 29(1):67-72. PubMed ID: 8929827
[TBL] [Abstract][Full Text] [Related]
10. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
Halleen JM
Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
[TBL] [Abstract][Full Text] [Related]
11. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
13. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
15. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
16. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
Wada N; Fujisaki M; Ishii S; Ikeda T; Kitajima M
Breast Cancer; 2001; 8(2):131-7. PubMed ID: 11342986
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
Capeller B; Caffier H; Sütterlin MW; Dietl J
Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
